All AstraZeneca articles
-
NewsSummer studentship: Shen explores how a novel peptide can destabilise the outer membrane of E. coli
Li Shen reports back on his AMI-sponsored summer studentship which investigated a novel antibiotic adjuvant at the Centre for Bacterial Resistance Biology, Imperial College London.
-
NewsAI could accelerate protein engineering – key for developing new medicines
An AI approach developed by researchers from the University of Sheffield and AstraZeneca could make it easier to design proteins needed for new treatments.
-
NewsClinical trial underway for potential Long COVID treatment
A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca’s long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid.
-
NewsAsthma and antibiotic use may predict nasal polyp recurrence after endoscopic sinus surgery
A recent study suggests that patients with chronic rhinosinusitis, who had undergone endoscopic sinus surgery, have a higher chance of undergoing revision sinus surgery that removes nasal polyps if they have asthma and are using antibiotics.
-
NewsResearchers investigate bunyaviruses and picornaviruses in bid to stave off next pandemic
A $13 million per year grant will enable researchers to accelerate their investigations of bunyaviruses, which include life-threatening respiratory and hemorrhagic fever viruses, and picornaviruses, notably enterovirus D68.
-
NewsNew antibiotic kills pathogenic bacteria, but spares healthy gut microbes
Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the mouse gut.
-
NewsScientists build human lungs in dish to test drugs
Scientists have developed a step-by-step blueprint to create advanced human lung models in the lab, which they say will accelerate the discovery and development of new drugs and reduce reliance on animal testing.
-
NewsChange in genetics of SARS-CoV-2 evolved to counter weakness caused by the virus’s initial mutation
Researchers at Johns Hopkins Medicine say their new studies suggest that the first pandemic-accelerating mutation in the SARS-CoV-2 virus, which causes COVID-19, evolved as a way to correct vulnerabilities caused by the mutation that started the SARS-CoV-2 pandemic.